Syros Pharmaceuticals to Present at Future Medical and Investor Conferences

Syros Pharmaceuticals, a biopharmaceutical company listed on NASDAQ under the ticker SYRS, is dedicated to revolutionizing the initial treatment of blood cancers. The company has announced plans to present new data from the SELECT-AML-1 Phase 2 clinical trial at the upcoming Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, Texas, from September 4-7. Furthermore, Syros will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York City from September 9-11.

At the SOHO Annual Meeting, Syros will unveil findings from the randomized segment of the SELECT-AML-1 trial. This study investigates the efficacy of tamibarotene in combination with venetoclax and azacitidine in adults with newly diagnosed acute myeloid leukemia (AML) who exhibit overexpression of the RARA gene and are unsuitable for standard induction therapy. The presentation is scheduled for Wednesday, September 4, 2024, from 5:15-6:30 PM CT at the George R. Brown Convention Center. The poster for this presentation, numbered AML-347, will be accessible on Syros' website following the session.

In addition to the SOHO meeting, Syros will also engage in the H.C. Wainwright 26th Annual Global Investment Conference. Scheduled for Monday, September 9, 2024, at 11:30 AM ET, the conference will take place at the Lotte New York Palace. A live webcast of Syros' presentation will be streamed via the Investors & Media section of the company's website, with a replay available for 30 days post-presentation.

Syros Pharmaceuticals is at the forefront of developing innovative treatments for hematologic malignancies, particularly for patients whose diseases have not responded to other targeted therapies. The company’s lead candidate, tamibarotene, is an oral selective RARα agonist designed for frontline patients with higher-risk myelodysplastic syndrome exhibiting RARA gene overexpression. 

Syros' commitment to advancing hematologic oncology care is reflected in its rigorous scientific approach and focus on patient outcomes. By presenting at key industry conferences and engaging with the investment community, Syros aims to foster collaboration and drive forward its clinical programs. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!